


My Annual Fund Fundraising Page
FRED AND CHRIS PHILLIPS
FRED AND CHRIS PHILLIPS
In furtherance of our commitment to help find a cure for cystic fibrosis, we are raising funds to support the Cystic Fibrosis Foundation’s Annual Fund. Contributions to the Annual Fund provide important, unrestricted dollars that are funneled to partnering biotech companies for research to help develop new treatments that we believe will, in our lifetime, lead to that cure.
The latest drug,Trikafta, developed by the biotech company, Vertex, right here in San Diego, has been a miracle drug and lifeline for many CF patients. Our son, Peter (pictured here with his family), is one of those beneficiaries, and, at 47, is healthier than he has been for many years. However, there are many patients for which the drug has no effect because they have a less common genotype. Consequently, they are left behind. You can imagine the heartbreak for those patients and their families knowing that a cure is coming but perhaps not soon enough.
Trikafta, is a treatment, not a cure. It is the beginning. Curing the disease is the end. Please consider making a contribution today.
Your support will help make a difference for all those with CF and their families. Thank you!
The latest drug,Trikafta, developed by the biotech company, Vertex, right here in San Diego, has been a miracle drug and lifeline for many CF patients. Our son, Peter (pictured here with his family), is one of those beneficiaries, and, at 47, is healthier than he has been for many years. However, there are many patients for which the drug has no effect because they have a less common genotype. Consequently, they are left behind. You can imagine the heartbreak for those patients and their families knowing that a cure is coming but perhaps not soon enough.
Trikafta, is a treatment, not a cure. It is the beginning. Curing the disease is the end. Please consider making a contribution today.
Your support will help make a difference for all those with CF and their families. Thank you!
JUN
30
30

Comments